Selected studies of allo-HCT in relapsed follicular lymphoma
| Study . | Design . | Patients, n . | Conditioning regimen . | NRM, % (follow-up, y) . | GVHD . | PFS/DFS, % (follow-up, y) . | OS, % (follow-up, y) . |
|---|---|---|---|---|---|---|---|
| van Besien et al27 | Registry | 176 | 100% HLA-MSD, 68% TBI based, 32% non-TBI based. | 30 (5) | — | 45 (5) | 51 (5) |
| NCCN Lymphoma Outcomes; Evens et al28 | Multicenter | 48 | 63% HLA-MSD; 37% HLA-MUD; 31% fludarabine, melphalan; 29% TBI based; 23% busulfan, fludarabine; 17% other. | 24 (3) | — | 52 (3) | 63 (3) |
| Rezvani et al29 | Multicenter | 62 | 55% related, 45% unrelated; 2 Gy fludarabine. | 42 (3) | Acute GVHD: grade 2, 45%; grade 3, 8%; grade 4, 10%. | 54 (3) | 67 (3) |
| CIBMTR; Shah et al30 | Registry | 1629 | HLA-MSD, HLA-MUD, mm-URD, RIC, or NMA. | 24-30 (4) | Grades 2-4, 35-38% (180 d). | 31-37 (4) | 46-51 (4) |
| Tombyln et al31 | Prospective* | 8 | HLA-MSD, RIC (fludarabine, cyclophosphamide, rituximab). | 0 (3) | Grades 2-4, 0%. | 86 (3) | 100 (3) |
| Study . | Design . | Patients, n . | Conditioning regimen . | NRM, % (follow-up, y) . | GVHD . | PFS/DFS, % (follow-up, y) . | OS, % (follow-up, y) . |
|---|---|---|---|---|---|---|---|
| van Besien et al27 | Registry | 176 | 100% HLA-MSD, 68% TBI based, 32% non-TBI based. | 30 (5) | — | 45 (5) | 51 (5) |
| NCCN Lymphoma Outcomes; Evens et al28 | Multicenter | 48 | 63% HLA-MSD; 37% HLA-MUD; 31% fludarabine, melphalan; 29% TBI based; 23% busulfan, fludarabine; 17% other. | 24 (3) | — | 52 (3) | 63 (3) |
| Rezvani et al29 | Multicenter | 62 | 55% related, 45% unrelated; 2 Gy fludarabine. | 42 (3) | Acute GVHD: grade 2, 45%; grade 3, 8%; grade 4, 10%. | 54 (3) | 67 (3) |
| CIBMTR; Shah et al30 | Registry | 1629 | HLA-MSD, HLA-MUD, mm-URD, RIC, or NMA. | 24-30 (4) | Grades 2-4, 35-38% (180 d). | 31-37 (4) | 46-51 (4) |
| Tombyln et al31 | Prospective* | 8 | HLA-MSD, RIC (fludarabine, cyclophosphamide, rituximab). | 0 (3) | Grades 2-4, 0%. | 86 (3) | 100 (3) |
mm-URD, mismatched unrelated donor; NCCN, National Cancer Care Network.
Early closure from low accrual.